Takayuki Yoshino on the DESTINY-CRC01 trial

Takayuki Yoshino (National Cancer Center Hospital East, Kashiwa, Japan) discusses the DESTINY-CRC01 trial on trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00086-3/fulltext Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv